Asli Isa Neshandar, Mosaffa Nariman, Mogharrabi Mehdi, Hooman Aref, Tabei Faraj, Javadi Hamid, Shafei Babak, Seyedabadi Mohammad, Assadi Majid
Department of Nuclear Medicine, Taleghani Hospital.
Nucl Med Commun. 2010 Apr;31(4):307-10. doi: 10.1097/MNM.0b013e3283354c9e.
We evaluated the potential detrimental cytogenetic effects of Tc-methoxyisobutyl isonitrile (MIBI) and I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, respectively.
Mononuclear leukocytes were isolated both before and after radiopharmaceutical administration and subsequently cultured. Micronuclei frequency was then assessed and microscopic evaluation of apoptosis was conducted.
Small statistically insignificant augmentation in the percentage of micronuclei from 10.9+/-3.8 to 11.3+/-2.4% was observed in the Tc-MIBI group. In contrast, I elicited a notable augmentation of micronuclei from 6.3+/-2.2 to 9.6+/-3.1 at 3.7 GBq, and 6+/-1.5 to 9.2+/-2.7 at 5.55 GBq (P<0.05).
Our results showed that there were no remarkable alterations either in the micronuclei incidence or in the percentage of apoptotic lymphocytes after in-vivo exposure to radiopharmaceutical imaging, which provides evidence to reduce the growing concern about the safety issue of cardiac imaging with Tc-MIBI, whereas the deleterious effects of I must be considered when it is applied to thyroid cancer treatment.
我们分别评估了锝-甲氧基异丁基异腈（MIBI）和碘-131对接受放射性药物进行心脏成像或甲状腺癌治疗的患者潜在的有害细胞遗传学影响。
在放射性药物给药前后分离单核白细胞，随后进行培养。然后评估微核频率并进行凋亡的显微镜评估。
在锝-甲氧基异丁基异腈组中，观察到微核百分比从10.9±3.8% 小幅增加至11.3±2.4%，但在统计学上无显著意义。相比之下，碘-131在3.7GBq时使微核显著增加，从6.3±2.2% 增至9.6±3.1%，在5.55GBq时从6±1.5% 增至9.2±2.7%（P<0.05）。
我们的结果表明，体内暴露于放射性药物成像后，微核发生率或凋亡淋巴细胞百分比均无明显变化，这为减少对锝-甲氧基异丁基异腈心脏成像安全性问题日益增加的担忧提供了证据，而在将碘-131应用于甲状腺癌治疗时，必须考虑其有害影响。
